Found 1697 clinical trials
enrolling Trial
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 22 Feb, 2023
COPD-ICU Multicentre Prospective Observational Register (COPD-ICU)
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 21 Feb, 2023
second sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 21 Feb, 2023
scrumsecond sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 22 Feb, 2023
- 1 location
scrumsecond sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023
scrumsecond sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023
scrumsecond synclink test
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023
Email body
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023
Email body 1
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023
Email body 2
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023